
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow a systematic approach:<br><br>### Step 1: List the Key Functional Markers<br>- **MTCO2P12**: Mitochondrial gene, often involved in energy metabolism.<br>- **GSTM1**: Glutathione S-transferase, involved in detoxification.<br>- **H3-3A, H3-3B, H2AJ, H2AZ1**: Histone proteins, involved in chromatin structure and gene regulation.<br>- **GABARAP**: Involved in autophagy and intracellular trafficking.<br>- **CA2**: Carbonic anhydrase, involved in pH regulation and ion transport.<br>- **PRKACB**: Protein kinase, involved in signal transduction.<br>- **CXCL14**: Chemokine, involved in immune response and cell migration.<br>- **GPX1**: Glutathione peroxidase, involved in oxidative stress response.<br>- **ESR1**: Estrogen receptor, involved in hormone signaling.<br>- **GATA3**: Transcription factor, involved in cell differentiation and development.<br>- **IGF1R**: Insulin-like growth factor receptor, involved in growth and survival signaling.<br><br>### Step 2: List the Key Cell Type Markers<br>- **ESR1**: Estrogen receptor alpha, a key marker for luminal epithelial cells in breast tissue.<br>- **GATA3**: A transcription factor highly expressed in luminal epithelial cells and often used as a marker for breast cancer subtypes.<br>- **CXCL14**: While broadly expressed, it is often associated with epithelial cells and has roles in tumor microenvironment interactions.<br>- **IGF1R**: Often expressed in epithelial cells, involved in growth and survival pathways.<br>- **SLC39A6**: Zinc transporter, associated with epithelial cells, particularly in breast tissue.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and recent literature, we can confirm that:<br>- **ESR1** and **GATA3** are strongly associated with luminal epithelial cells in breast tissue.<br>- **CXCL14** and **IGF1R** are also expressed in epithelial cells, supporting the epithelial origin.<br>- **SLC39A6** is known to be expressed in breast epithelial cells.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of **ESR1**, **GATA3**, and other epithelial markers, the most probable general cell type is **luminal epithelial cells**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal A Breast Cancer Cells**: Characterized by high expression of ESR1 and GATA3, typically hormone receptor-positive.<br>2. **Luminal B Breast Cancer Cells**: Similar to Luminal A but with higher proliferation markers and possibly lower ESR1 expression.<br>3. **Normal Luminal Epithelial Cells**: Non-cancerous counterpart, expressing ESR1 and GATA3 but without cancer-associated markers.<br><br>The most likely subtype, given the context of breast cancer tissue and the presence of ESR1 and GATA3, is **Luminal A Breast Cancer Cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of luminal epithelial cells, specifically Luminal A breast cancer cells. This conclusion is supported by the high expression of key markers such as ESR1 and GATA3, which are characteristic of this subtype.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    To validate the annotation result, let's follow the outlined steps:<br><br>### Step 1: Marker Consistency<br>- **Markers in the List**: The proposed annotation uses markers such as ESR1, GATA3, CXCL14, IGF1R, and SLC39A6, which are all present in the provided marker list.<br>- **Consistency with Cell Type**: The markers ESR1 and GATA3 are well-known markers for luminal epithelial cells, particularly in breast tissue. CXCL14 and IGF1R also support an epithelial origin, and SLC39A6 is associated with breast epithelial cells. This is consistent with the annotation of luminal epithelial cells, specifically Luminal A breast cancer cells.<br><br>### Step 2: Mixed Cell Type Consideration<br>- **Potential Mixed Populations**: The markers used strongly support a single cell type, luminal epithelial cells, with no strong evidence of multiple distinct cell types based on the high-ranking markers provided. Therefore, there is no immediate indication of a mixed cell population that requires further investigation.<br><br>### Conclusion<br>The annotation result is consistent with the provided marker list and the identified cell type. The markers used are appropriate and support the conclusion of Luminal A breast cancer cells.<br><br>Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">luminal epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Luminal A Breast Cancer Cells</li><li>Luminal B Breast Cancer Cells</li><li>Normal Luminal Epithelial Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a thorough and systematic approach to identifying the cell type from the single-cell dataset derived from breast cancer tissue. The analysis correctly identifies key markers such as ESR1 and GATA3, which are well-established indicators of luminal epithelial cells, particularly in the context of breast cancer. The annotation also considers other markers like CXCL14, IGF1R, and SLC39A6, which support the epithelial origin and are relevant to breast tissue, indicating a balanced consideration of multiple markers.<br><br>The annotation process effectively captures the general picture of the cell populations by identifying the most probable general cell type as luminal epithelial cells and further specifying the subtype as Luminal A breast cancer cells. This is consistent with the expression of ESR1 and GATA3, which are characteristic of this subtype. The analysis also considers potential subtypes such as Luminal B breast cancer cells and normal luminal epithelial cells, providing a comprehensive view of the possible cell types present.<br><br>However, there are a few areas where the analysis could be improved. While the annotation does a good job of considering multiple markers, it could benefit from a more detailed discussion of the rank and relative importance of each marker, especially those appearing earlier in the list. Additionally, the analysis could explore the potential for mixed cell populations more thoroughly, even if the current evidence strongly supports a single cell type.<br><br>Overall, the annotation is scientifically accurate, well-balanced in its use of markers, and provides a comprehensive view of the cell types present. There are no obvious misclassifications or oversights, and the validation process confirms the consistency and appropriateness of the markers used.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    